<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040781</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01874</org_study_id>
    <secondary_id>ADVL0016</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000069406</secondary_id>
    <nct_id>NCT00040781</nct_id>
    <nct_alias>NCT00050739</nct_alias>
  </id_info>
  <brief_title>Gefitinib in Treating Children With Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of gefitinib in treating children who have&#xD;
      refractory solid tumors. Gefitinib may stop the growth of cancer cells by blocking the&#xD;
      enzymes necessary for tumor cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of gefitinib in children with refractory solid&#xD;
      tumors.&#xD;
&#xD;
      II. Determine the dose-limiting toxicity of this drug in these patients. III. Determine the&#xD;
      pharmacokinetics of this drug in these patients. IV. Determine, preliminarily, the antitumor&#xD;
      activity of this drug in these patients.&#xD;
&#xD;
      V. Correlate the pharmacogenetic polymorphisms of this drug with pharmacokinetics and&#xD;
      pharmacodynamics in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. If myelosuppression is found to be the&#xD;
      dose-limiting toxicity, patients are stratified according to prior therapy (more than 2&#xD;
      multiagent chemotherapy regimens or radiotherapy to more than 20% of the bone marrow or stem&#xD;
      cell transplantation with or without total body irradiation vs more than 2 single-agent phase&#xD;
      I or phase II agents) and extent of disease (bone marrow involvement vs meeting none of the&#xD;
      stratum I criteria).&#xD;
&#xD;
      Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-45 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by the Common Terminology Criteria (CTC) version 2.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT defined as hematologic and non-hematologic toxicities toxicities attributable to drug administration occurring during or immediately subsequent to the first course as assessed by CTC version 2.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of gefitinib</measure>
    <time_frame>At baseline, at 1, 2, 4, 6, 8, 12, and 24 hours after administration, at days 21 and 28, and at day 28 of subsequent courses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of gefitinib according to Response Evaluation Criteria in Solid Tumor (RECIST)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor at original diagnosis&#xD;
&#xD;
          -  Refractory to conventional therapy and other therapies of higher priority according to&#xD;
             the COG Phase I/II priority list or no conventional therapy exists&#xD;
&#xD;
          -  No primary CNS tumors or known metastases to the CNS&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (over 10 years of age)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (10 years of age and under)&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL (RBC transfusion allowed)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 3 times ULN&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
          -  Creatinine normal for age&#xD;
&#xD;
          -  Glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  At least 6 months since prior allogeneic stem cell transplantation (SCT)&#xD;
&#xD;
               -  No evidence of active graft-versus-host disease&#xD;
&#xD;
          -  At least 1 week since prior biologic agents&#xD;
&#xD;
          -  At least 1 week since prior hematopoietic growth factors&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No concurrent tamoxifen&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative (small port) radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or more&#xD;
             of the pelvis (6 weeks for radiotherapy to other substantial amount of bone marrow)&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent drugs with known corneal toxicity (e.g., chlorpromazine, Amiodarone, or&#xD;
             chloroquine)&#xD;
&#xD;
          -  No concurrent enzyme-activating anticonvulsants&#xD;
&#xD;
          -  No concurrent proton pump inhibitors or H-2 blockers within 4 hours of gefitinib&#xD;
             administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Najat Daw</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

